Table 1.

Summary of key efficacy and safety parameters in the maximum tolerated dose-expansion cohorts of the two phase I studies of twice-weekly and weekly single-agent ixazomib in patients with relapsed/refractory multiple myeloma

Parameter	Twice-weekly study, ixazomib dose 2.0 mg/m2 [n (%)]	Weekly study, ixazomib dose 2.97 mg/m2 [n (%)]
Response-evaluable patients (n)	39	30
Response ratea	6 (15)	8 (27)
Safety population (n)	40	31
Any grade 3 AE	31 (78)	24 (77)
Any grade 4 AE	19 (48)	11 (35)
Dose modification	27 (68)	18 (58)
Discontinuation due to AE	8 (20)	4 (13)

AE adverse event

^aConfirmed or unconfirmed best response of complete response or partial response